MITOXCELAI
Live / Applied — Non-final action mailed (as of 11 Nov 2025)
What this means for you
Not registered yet, but its 12 Jun 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99230657
- Mark type
- Stylized text
- Filed
- 12 Jun 2025
- Attorney of record
- Jared L. DuJack
Goods and services
- Class 005 — Pharmaceuticals: Synthetic peptides for the treatment of cancer, age-related disorders, age-related diseases, skin conditions, radiation damage, obesity, mitochondrial disease, neurodegenerative disease, and metabolic conditions; Pharmaceutical preparations for the treatment and prevention of cancer, age-related disorders, age-related diseases, skin conditions, radiation damage, obesity, mitochondrial disease, neurodegenerative disease, and metabolic conditions; Pharmaceutical preparations for gene therapy for the treatment of age-related disorders; Pharmaceutical preparations for gene therapy for the treatment of cancer; Medicated skin preparation for use in treating skin conditions, aging, mitochondrial conditions, and senescent cells
- Class 042 — Scientific and technological services: Medical research services; Medical research in the field of mitochondrial health and mitochondrial disease; Medical research in the field of metabolic health and metabolic conditions; Medical research in the field of anti-aging; Medical research in the field of senescent cells; Medical research in the field of age-related disorders; Medical research in the field of neurodegenerative health and neurodegenerative disease; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Pharmaceutical research in the field of mitochondrial disease; Pharmaceutical research in the field of metabolic conditions; Pharmaceutical research in the field of neurodegenerative disease; Gene therapy research; Testing of pharmaceuticals for cell and gene therapies; Development of pharmaceuticals for cell and gene therapies
- Class 044 — Medical, beauty and agricultural services: Medical services, namely, anti-aging services; Medical services, namely, prevention and treatment of cancer, age-related disorders, age-related diseases, skin conditions, radiation damage, obesity, mitochondrial disease, neurodegenerative disease, and metabolic conditions; Medical services in the field of mitochondrial health and mitochondrial disease; Medical services in the field of metabolic health and metabolic conditions; Medical services in the field of anti-aging; Medical services in the field of senescent cells; Medical services in the field of age-related disorders; Medical services in the field of neurodegenerative health and neurodegenerative disease; Medical advisory services; Medical testing services; Medical testing services relating to the diagnosis and treatment of disease
Owner
- SENOTHERAPEUTIX, Inc., Surfside, FL, US
Prosecution history
- 10 Feb 2026 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 10 Feb 2026 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 11 Nov 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 11 Nov 2025 — NON-FINAL ACTION E-MAILED
- 11 Nov 2025 — NON-FINAL ACTION WRITTEN
- 31 Oct 2025 — ASSIGNED TO EXAMINER
- 22 Oct 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 12 Jun 2025 — APPLICATION FILING RECEIPT MAILED
- 12 Jun 2025 — NEW APPLICATION ENTERED